(Q42551398)

2 November 2017

title

Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis (English)

1 reference

2 November 2017

0 references

E A Perez

1

1 reference

2 November 2017

R M Navari

2

1 reference

2 November 2017

H G Kaplan

3

1 reference

2 November 2017

R J Gralla

4

1 reference

2 November 2017

S M Grunberg

5

1 reference

2 November 2017

R H Palmer

6

1 reference

2 November 2017

D Fitts

7

1 reference

2 November 2017

language of work or name

1 reference

1 January 1997

1 reference

Supportive Care in Cancer

2 November 2017

published in

1 reference

2 November 2017

volume

5

1 reference

2 November 2017

issue

1

1 reference

2 November 2017

page(s)

31-37

1 reference

Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group

2 November 2017

cites work

1 reference

12 December 2020

An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy

1 reference

12 December 2020

The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis.

1 reference

12 December 2020

A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group

1 reference

12 December 2020

A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group

1 reference

12 December 2020

Cancer therapy, vomiting, and antiemetics.

1 reference

12 December 2020

A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group

1 reference

12 December 2020

The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.

1 reference

12 December 2020

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin

1 reference

12 December 2020

Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. The Nordic Antiemetic Trial Group.

1 reference

12 December 2020

Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group

1 reference

12 December 2020

Fractionated chemotherapy--granisetron or conventional antiemetics? The Granisetron Study Group

1 reference

12 December 2020

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy

1 reference

12 December 2020

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

12 December 2020

Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide

1 reference

12 December 2020

Antiemetic Efficacy of Tropisetron in Patients Failing Previous Antiemetic Therapy

1 reference

12 December 2020

The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis

1 reference

12 December 2020

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

1 reference

12 December 2020

Identifiers

DOI

10.1007/S005200050037

1 reference

Dimensions Publication ID

2 November 2017

1054517541

0 references

1 reference